Notably, our time-course analysis suggests that when using a sub-lethal dose of cisplatin, which does not carry risk of systemic toxicity, CXCL1 may be a strong potential candidate biomarker to predict and monitor different stages of cisplatin-AKI, including the subclinical phase. This evidence concerns the gene CXCL1 and acute kidney injury.